VH 3739937
Alternative Names: GSK 3739937; VH-3739937; VH-937Latest Information Update: 07 Aug 2024
At a glance
- Originator GlaxoSmithKline; ViiV Healthcare
- Developer GSK; ViiV Healthcare
- Class Antiretrovirals
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV infections
Most Recent Events
- 01 Aug 2024 ViiV Healthcare plans a phase I trial for HIV infection (In volunteers) in USA (PO) (NCT06533280)
- 01 May 2024 VH 3739937 is still in phase II trials for HIV infections in Unknown locations (GSK Pipeline)
- 03 Mar 2024 Pharmacodynamics data from preclinical studies in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI-2024)